{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:46:02Z","timestamp":1784940362643,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic role of BAP1, WT1 and calretinin expression and their combinations in pre-treatment tumor samples by immunohistochemical (IHC) staining.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study included consecutive PM patients treated with chemotherapy alone at a University hospital between 2009 and 2020. BAP1 analyses were performed on formalin-fixed, paraffin-embedded tumor tissue samples of the patients, while WT1 and calretinin information were obtained from the histopathological diagnosis records.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the total 107 patients included, 64% had loss of BAP1 expression, whereas 77% had WT1 and 86% had calretinin expression. Patients with the presence of BAP1 expression, one or both of the other two markers, or loss of expression of all three markers (unfavorable status) were more likely to not respond to chemotherapy than those with the presence of all three markers or loss of BAP1 expression and expression of one or two other markers (favorable status) (<jats:italic>p<\/jats:italic>\u2009=\u20090.001).\u00a0Median survival time of patients with favorable and unfavorable status was 15\u2009\u00b1\u20091.7 and 8.0\u2009\u00b1\u20092.4\u00a0months, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.027).\u00a0After adjustment for histopathology and stage, loss of BAP1 (HR\u2009=\u20090.54, 95%CI 0.35\u20130.83), WT1 (1.75, 1.06\u20132.90), calretinin (2.09, 1.14\u20133.84) expression and favourable panel (0.50, 0.27\u20130.92) was associated with prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The IHC biomarkers BAP1, WT1, and calretinin, used in the routine diagnosis of PM and their combinations, are the first biomarkers associated with response to chemotherapy and may be a useful tool to select patients for first-line platinum pemetrexed treatment in PM patients. Validation in a large cohort is ongoing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05565-6","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T06:02:02Z","timestamp":1706335322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["BAP1, Wilms\u2019 tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma"],"prefix":"10.1007","volume":"150","author":[{"given":"Tuna Han","family":"Yuce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntulu","family":"Ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Metintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Dundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluf Dimitri","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Panou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Metintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"5565_CR1","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","volume":"13","author":"SG Armato 3rd","year":"2018","unstructured":"Armato SG 3rd, Nowak AK (2018) Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol 13:1012\u20131021","journal-title":"J Thorac Oncol"},{"key":"5565_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/ijc.28218","volume":"133","author":"W Blum","year":"2013","unstructured":"Blum W, Schwaller B (2013) Calretinin is essential for mesothelioma cell growth\/survival in vitro: a potential new target for malignant mesothelioma therapy? Int J Cancer 133:2077\u20132088","journal-title":"Int J Cancer"},{"key":"5565_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","volume":"13","author":"R Bueno","year":"2018","unstructured":"Bueno R, Opitz I, IASLC Mesothelioma Taskforce (2018) Surgery in malignant pleural mesothelioma. J Thorac Oncol 13:1638\u20131654","journal-title":"J Thorac Oncol"},{"key":"5565_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","volume":"146","author":"L Cantini","year":"2020","unstructured":"Cantini L, Pecci F, Murrone A et al (2020) Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis. Lung Cancer 146:318\u2013326","journal-title":"Lung Cancer"},{"key":"5565_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-10-179","volume":"10","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ferris LK, Baumann F et al (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10:179","journal-title":"J Transl Med"},{"key":"5565_CR6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"M Carbone","year":"2020","unstructured":"Carbone M, Harbour JW, Brugarolas J et al (2020) Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov 10:1103\u20131120","journal-title":"Cancer Discov"},{"key":"5565_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12094-013-1146-6","volume":"16","author":"S Cedr\u00e9s","year":"2014","unstructured":"Cedr\u00e9s S, Montero MA, Zamora E et al (2014) Expression of Wilms\u2019 tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. Clin Transl Oncol 16:776\u2013782","journal-title":"Clin Transl Oncol"},{"key":"5565_CR8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","volume":"9","author":"DB Chapel","year":"2020","unstructured":"Chapel DB, Schulte JJ, Husain AN, Krausz T (2020) Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 9:S3\u2013S27","journal-title":"Transl Lung Cancer Res"},{"key":"5565_CR9","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323\u20135337","journal-title":"Clin Cancer Res"},{"key":"5565_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","volume":"28","author":"M Cigognetti","year":"2015","unstructured":"Cigognetti M, Lonardi S, Fisogni S et al (2015) BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol 28:1043\u20131057","journal-title":"Mod Pathol"},{"key":"5565_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/BLT.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK et al (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89:716\u2013724","journal-title":"Bull World Health Organ"},{"key":"5565_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.603223","volume":"11","author":"E Dudnik","year":"2021","unstructured":"Dudnik E, Bar J, Moore A et al (2021) BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-Ribose) polymerase inhibitors. Front Oncol 11:603223","journal-title":"Front Oncol"},{"key":"5565_CR13","doi-asserted-by":"publisher","first-page":"77872","DOI":"10.18632\/oncotarget.20845","volume":"8","author":"T Eguchi","year":"2017","unstructured":"Eguchi T, Kadota K, Mayor M et al (2017) Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget 8:77872\u201377882","journal-title":"Oncotarget"},{"key":"5565_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","volume":"47","author":"M Farzin","year":"2015","unstructured":"Farzin M, Toon CW, Clarkson A et al (2015) Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 47:302\u2013307","journal-title":"Pathology"},{"key":"5565_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","volume":"19","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, Dulloo S, Harber J (2022) Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol 19:573\u2013584","journal-title":"Nat Rev Clin Oncol"},{"key":"5565_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/ijms20020429","volume":"20","author":"A Guazzelli","year":"2019","unstructured":"Guazzelli A, Meysami P, Bakker E et al (2019) BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci 20:429","journal-title":"Int J Mol Sci"},{"key":"5565_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","volume":"142","author":"AN Husain","year":"2018","unstructured":"Husain AN, Colby TV, Ord\u00f3\u00f1ez NG et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 142:89\u2013108","journal-title":"Arch Pathol Lab Med"},{"key":"5565_CR18","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","volume":"6","author":"SC Kao","year":"2011","unstructured":"Kao SC, Klebe S, Henderson DW et al (2011) Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 6:1923\u20131929","journal-title":"J Thorac Oncol"},{"key":"5565_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd et al (2018) Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1343\u20131373","journal-title":"J Clin Oncol"},{"key":"5565_CR20","doi-asserted-by":"publisher","first-page":"TPS139","DOI":"10.1200\/jco.2011.29.15_suppl.tps139","volume":"29","author":"LM Krug","year":"2011","unstructured":"Krug LM, Tsao AS, Kass S (2011) Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 29:TPS139","journal-title":"J Clin Oncol"},{"key":"5565_CR21","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/bjc.2014.478","volume":"111","author":"A Linton","year":"2014","unstructured":"Linton A, Pavlakis N, O\u2019Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N (2014) Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 111:1860\u20131869","journal-title":"Br J Cancer"},{"key":"5565_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","volume":"17","author":"A Louw","year":"2022","unstructured":"Louw A, Panou V, Szejniuk WM et al (2022) BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol 17:921\u2013930","journal-title":"J Thorac Oncol"},{"key":"5565_CR23","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","volume":"13","author":"RJ May","year":"2007","unstructured":"May RJ, Dao T, Pinilla-Ibarz J et al (2007) Peptide epitopes from the Wilms\u2019 tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 13:4547\u20134555","journal-title":"Clin Cancer Res"},{"key":"5565_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","volume":"46","author":"SM McGregor","year":"2015","unstructured":"McGregor SM, Dunning R, Hyjek E et al (2015) BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol 46:1670\u20131678","journal-title":"Hum Pathol"},{"key":"5565_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","volume":"60","author":"SM McGregor","year":"2017","unstructured":"McGregor SM, McElherne J, Minor A et al (2017) BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. Hum Pathol 60:86\u201394","journal-title":"Hum Pathol"},{"key":"5565_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S et al (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565\u2013576","journal-title":"J Thorac Oncol"},{"key":"5565_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","volume":"41","author":"V Panou","year":"2015","unstructured":"Panou V, Vyberg M, Weinreich UM et al (2015) The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 41:486\u2013495","journal-title":"Cancer Treat Rev"},{"key":"5565_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R et al (2022) First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 33:488\u2013499","journal-title":"Ann Oncol"},{"key":"5565_CR29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/diagnostics10060386","volume":"10","author":"F Pezzuto","year":"2020","unstructured":"Pezzuto F, Serio G, Fortarezza F et al (2020) Prognostic Value of Ki67 Percentage, WT-1 Expression and p16\/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study. Diagnostics (basel) 10:386","journal-title":"Diagnostics (basel)"},{"key":"5565_CR30","doi-asserted-by":"publisher","first-page":"1310478","DOI":"10.1155\/2017\/1310478","volume":"2017","author":"E Pulford","year":"2017","unstructured":"Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S (2017) Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis? Dis Markers 2017:1310478","journal-title":"Dis Markers"},{"key":"5565_CR31","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","volume":"34","author":"A Rimner","year":"2016","unstructured":"Rimner A, Zauderer MG, Gomez DR et al (2016) Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 34:2761\u20132768","journal-title":"J Clin Oncol"},{"key":"5565_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/0284186X.2021.1876246","volume":"60","author":"T Ringgaard Petersen","year":"2021","unstructured":"Ringgaard Petersen T, Panou V, Meristoudis C, Weinreich UM, R\u00f8e OD (2021) Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting. Acta Oncol 60:521\u2013527","journal-title":"Acta Oncol"},{"key":"5565_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1183\/09059180.00007014","volume":"24","author":"OD R\u00f8e","year":"2015","unstructured":"R\u00f8e OD, Stella GM (2015) Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev 24:115\u2013131","journal-title":"Eur Respir Rev"},{"key":"5565_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2559.2011.04108.x","volume":"60","author":"A Scattone","year":"2012","unstructured":"Scattone A, Serio G, Marzullo A et al (2012) High Wilms\u2019 tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma. Histopathology 60:472\u2013481","journal-title":"Histopathology"},{"key":"5565_CR35","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T et al (2020) ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 55:1900953","journal-title":"Eur Respir J"},{"key":"5565_CR36","unstructured":"Takeshima Y, Inai K, Ishikawa Y, Oka T, Hiroshima K (2010) The trial of differentiation grading of epithelioid mesothelioma with reference to its clinicopathological significance. In: 10th International Conference of the International Mesothelioma Interest Group, p 175"},{"key":"5565_CR37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.pathol.2016.08.003","volume":"48","author":"B Thapa","year":"2016","unstructured":"Thapa B, Walkiewicz M, Murone C et al (2016) Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. Pathology 48:660\u2013665","journal-title":"Pathology"},{"key":"5565_CR38","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L et al (2018) British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73:i1\u2013i30","journal-title":"Thorax"},{"key":"5565_CR39","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","volume":"23","author":"MG Zauderer","year":"2017","unstructured":"Zauderer MG, Tsao AS, Dao T et al (2017) A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res 23:7483\u20137489","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05565-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:03:58Z","timestamp":1711112638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05565-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["5565"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05565-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"38"}}